<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- Created by BusinessWire - EDGAR Online Xcelerate V6.13.8 -->
<!-- Round: 3 -->
<!-- Creation date: 2012-05-09T14:17:12Z -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ccrn="http://crosscountryhealthcare.com/20120331" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ccrn-20120331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE88446---1210-Q0006_STD_0_20120430_0" unitRef="shares" decimals="INF">30740370</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE88446---1210-Q0006_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">9858000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">1038000</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">-2812000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">53504000</us-gaap:LiabilitiesCurrent>
  <us-gaap:IndefiniteLivedTrademarks contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">52099000</us-gaap:IndefiniteLivedTrademarks>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">1955000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">638000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">1362000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">16777000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">16738000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">7041000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">8915000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Assets contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">334651000</us-gaap:Assets>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">95000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">334651000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">73841000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:CommonStockValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">8946000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">10746000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AssetsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">105449000</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">143550000</us-gaap:Goodwill>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">11323000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">5178000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:OtherShortTermInvestments contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">1792000</us-gaap:OtherShortTermInvestments>
  <us-gaap:Liabilities contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">85111000</us-gaap:Liabilities>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">1868000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">8628000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">43210000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">243434000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">249540000</us-gaap:StockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">20407000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">22960000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20120331_0" unitRef="iso4217_USD" decimals="-3">14735000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE88446---1210-Q0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">10957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1199000</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">-3373000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">46350000</us-gaap:LiabilitiesCurrent>
  <us-gaap:IndefiniteLivedTrademarks contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">52053000</us-gaap:IndefiniteLivedTrademarks>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">2180000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">701000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1294000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">25048000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">16332000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">7441000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">9500000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Assets contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">335910000</us-gaap:Assets>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">58000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">335910000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">71802000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:CommonStockValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">10648000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">12018000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AssetsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">104807000</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">143344000</us-gaap:Goodwill>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">10645000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">4002000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:OtherShortTermInvestments contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1691000</us-gaap:OtherShortTermInvestments>
  <us-gaap:Liabilities contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">86610000</us-gaap:Liabilities>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1879000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">9018000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">41657000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">243170000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">249300000</us-gaap:StockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">21195000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">16998000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE88446---1210-Q0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">15154000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">113000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">83000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="shares" decimals="-3">31103000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">372000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">2500000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">122046000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-880000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1061000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-227000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">644000</us-gaap:ShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1373000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">238000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">25000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">124000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">4117000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-1099000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">3950000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">399000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:CostOfServices contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">89070000</us-gaap:CostOfServices>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">28871000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">192000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-158000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-1617000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">207000</us-gaap:NetIncomeLoss>
  <us-gaap:CostsAndExpenses contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">120985000</us-gaap:CostsAndExpenses>
  <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">207000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">559000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AmortizationOfAcquisitionCosts contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">965000</us-gaap:AmortizationOfAcquisitionCosts>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1163000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-13000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">837000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="shares" decimals="-3">31190000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-17000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:Depreciation contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1841000</us-gaap:Depreciation>
  <us-gaap:PaymentsToAcquireOtherInvestments contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">43000</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">339000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
  <us-gaap:InterestExpense contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">728000</us-gaap:InterestExpense>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">352000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">CCRN</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">CROSS COUNTRY HEALTHCARE INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">2012-03-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">0001141103</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">999000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-36000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="shares" decimals="-3">30766000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;11.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;INCOME
TAXES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#x2019;s
effective tax rate for the full year is estimated to be
approximately 55.0% including the impact of discrete items. The
effective tax rate was 24.5% during the three months ended March
31, 2012. The lower tax rate in the three months ended March 31,
2012, was due to a loss in the period and certain discrete items.
Excluding these items, the effective tax rate in the three months
ended March 31, 2012, would have been 55.3%. The effective tax
rates excluding the reversal of uncertain tax positions were higher
than the statutory rates primarily due to the non-deductibility of
certain per diem expenses.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In accordance with
the &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Income Taxes&lt;/font&gt; Topic of the FASB ASC, a reconciliation of the
beginning and ending amounts of unrecognized tax benefits,
including estimated interest and penalties, is as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="95%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="77%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="21%" colspan="2"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(amounts
in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Balance at January
1, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="20%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;4,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Additions based on
tax provisions related to prior years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="20%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;20&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Additions based on
tax provisions related to current year&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="20%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;145&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Settlements of tax
positions related to prior years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(30&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="77%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Balance at March
31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="20%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;4,635&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;As of March 31,
2012, the Company had approximately $4.2 million of unrecognized
tax benefits, which would affect the effective tax rate if
recognized. During the three months ended March 31, 2012, the
Company had gross increases of $0.2 million to its current year
unrecognized tax benefits related to federal and state tax issues.
In addition, the Company had immaterial gross decreases to its
unrecognized tax benefits related to the settlement of a certain
state tax issue.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company
recognizes interest and penalties related to unrecognized tax
benefits in the provision for income taxes. The Company had accrued
approximately $0.7 million for the payment of interest and
penalties at both March 31, 2012 and December&amp;#xA0;31,
2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The tax years 2004,
2005 and 2008 through 2011 remain open to examination by the major
taxing jurisdictions to which the Company is subject, with the
exception of certain states in which the statute of limitations has
been extended.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">562000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">1200000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;4.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;EARNINGS
PER SHARE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In accordance with
the requirements of the &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Earnings Per Share&lt;/font&gt; Topic of the FASB ASC, basic earnings per
share is computed by dividing net (loss) income by the weighted
average number of shares outstanding (excluding unvested restricted
stock) and diluted earnings per share reflects the dilutive effects
of stock options and restricted stock (as calculated utilizing the
treasury stock method).Certain shares of common stock that are
issuable upon the exercise of options and vesting of restricted
stock have been excluded from the per share calculations because
their effect would have been anti-dilutive. Such shares amounted to
1,644,606 and 1,688,253 during the three months ended March 31,
2012 and 2011, respectively. For purposes of calculating net loss
per common share &amp;#x2013; diluted for the three months ended March
31, 2012, the Company excluded potentially dilutive shares of
70,700 from the calculation as their effect would have been
anti-dilutive due to the Company&amp;#x2019;s net loss in that
period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The following table
sets forth the components of the numerator and denominator for the
computation of the basic and diluted earnings per
share:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="26%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Three
Months Ended&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="26%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;March
31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="26%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(amounts
in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Net
(loss) income&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(584&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;207&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Net
(loss) income per common share-basic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(0.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;0.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Net
(loss) income per common share-diluted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(0.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;0.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Weighted-average
number of shares outstanding-basic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;30,766&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;31,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Plus
dilutive equity awards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;87&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Weighted-average
number of shares outstanding-diluted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;30,766&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;31,190&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;


&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">126672000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-551000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-WEIGHT: bold"&gt;8&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;.&lt;/font&gt;&lt;/font&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;STOCKHOLDERS&amp;#x2019;
EQUITY&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Stock Repurchase Program&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;During the three
months ended March 31, 2012, the Company repurchased, under its
February&amp;#xA0;2008 Board authorization, a total of 71,653 shares at
an average price of $5.22. The cost of such repurchases was
approximately $0.4 million. All of the common stock was retired.
During the three months ended March 31, 2011, the Company was
restricted from buying its common stock under its Credit
Agreement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;As of March 31,
2012, the Company may purchase up to an additional 942,443 shares
of common stock, subject to certain conditions in the
Company&amp;#x2019;s Credit Agreement. At March 31, 2012, the Company
had approximately 30.7&amp;#xA0;million shares of common stock
outstanding.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Share-Based Payments&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;During both the
three months ended March 31, 2012 and 2011, $0.6 million was
included in selling, general and administrative expenses related to
share-based payments.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-38000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-481000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">638000</us-gaap:ShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">1401000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;7.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;FAIR
VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company adopted
Update No. 2011-04, &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Fair Value Measurement (Topic 820), Amendments to Achieve Common
Fair Value Measurement and Disclosure Requirements in U.S. GAAP and
IFRSs,&lt;/font&gt; (ASU 2011-04) for its consolidated financial
statements in the first quarter of 2012. This ASU amends the fair
value measurement and disclosure guidance in ASC 820, &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Fair Value&lt;/font&gt; &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Measurement,&lt;/font&gt; to converge U.S. GAAP and International
Financial Reporting Standards (IFRS) requirements for measuring
amounts at fair value as well as disclosures about these
measurements. This amendment clarifies existing concepts regarding
the fair value principles and includes changed principles to
achieve convergence. The adoption of this standard did not change
the Company&amp;#x2019;s disclosures in the first quarter of
2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Fair Value Measurements and Disclosures&lt;/font&gt; Topic of the FASB
ASC, defines fair value as the exchange price that would be
received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants
on the measurement date. The &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Fair Value Measurements and Disclosures&lt;/font&gt; Topic also
establishes a fair value hierarchy which requires an entity to
maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. The standard
describes three levels of inputs that may be used to measure fair
value:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Level 1&lt;/font&gt;&amp;#x2014;Quoted prices in active markets for identical
assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Level 2&lt;/font&gt;&amp;#x2014;Observable inputs other than Level 1 prices
such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are
observable or can be corroborated by observable market data for
substantially the full term of the assets or
liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Level 3&lt;/font&gt;&amp;#x2014;Unobservable inputs that are supported by
little or no market activity and that are significant to the fair
value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;Fair
Value of Financial Instruments:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Unless otherwise
disclosed in the notes to the condensed consolidated financial
statements, the estimated fair value of financial assets and
liabilities approximates carrying value. The carrying amounts
reported in the consolidated balance sheets for cash and cash
equivalents, short-term cash investments, accounts receivable,
accounts payable and accrued expenses approximate fair value due to
the short-term nature of these instruments. Short-term cash
investments on the accompanying condensed consolidated balance
sheets relate to foreign investments in highly liquid time deposits
with original maturities less than one year but greater than three
months. At March 31, 2012 and December&amp;#xA0;31, 2011, other
long-term assets included approximately $0.9 million and $0.8
million, respectively, of foreign investments in highly liquid time
deposits with original maturities greater than one year. The
carrying value of these investments on the consolidated condensed
balance sheet approximates their fair value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company invests
its excess cash in highly rated overnight funds and other highly
rated liquid accounts. The Company is exposed to credit risk
associated with these investments. The Company minimizes its credit
risk relating to these positions by monitoring the financial
condition of the financial institutions involved and by primarily
conducting business with large, well established financial
institutions and diversifying its counterparties. The Company does
not currently anticipate nonperformance by any of its significant
counterparties.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company
performs ongoing credit evaluations of its customers&amp;#x2019;
financial conditions and, generally, does not require collateral.
The allowance for doubtful accounts represents the Company&amp;#x2019;s
estimate of uncollectible receivables based on a review of specific
accounts and the Company&amp;#x2019;s historical collection experience.
The Company writes off specific&amp;#xA0;accounts based on an ongoing
review of collectability as well as past experience with the
customer. The Company&amp;#x2019;s contract terms typically require
payment between 30 to 60 days from the date services are provided
and are considered past due based on the particular negotiated
contract terms. Overall, based on the large number of customers in
differing geographic areas, primarily throughout the United States
and its territories, the Company believes the concentration of
credit risk is limited.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The carrying
amounts of the revolving loan facility and term loan approximate
fair value as the interest rates are tied to a quoted variable
index. The fair value of these instruments is estimated using Level
2 inputs based&amp;#xA0;on quoted prices for similar
instruments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;Items
Measured at Fair Value on a Recurring Basis:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;At March 31, 2012
and December&amp;#xA0;31, 2011, the Company&amp;#x2019;s financial
assets/liabilities required to be measured on a recurring basis
were its deferred compensation liability included in other
long-term liabilities, its short-term cash investments, as well as
its marketable securities and long-term cash investments included
in other long-term assets. The Company utilizes Level 1 inputs to
value marketable securities and its deferred compensation
liability. The Company utilizes Level 2 inputs to value its short
and long-term cash investments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company did not
hold any Level 3 assets or liabilities that are measured on a
recurring basis at March&amp;#xA0;31, 2012 or December 31, 2011. The
Company&amp;#x2019;s marketable securities are measured using quoted
prices in active markets. Its short and long-term cash investments
are measured using quoted prices in inactive
markets.&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s deferred compensation
liability is measured using publicly available indices that define
the liability amounts, as per the plan documents.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The table which
follows summarizes the estimated fair values of the Company&amp;#x2019;s
financial assets and liabilities measured on a recurring basis as
of March 31, 2012 and December&amp;#xA0;31, 2011:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="70%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="100%" colspan="9"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Fair
Value Measurements&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="99%" colspan="8"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(amounts
in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="100%" colspan="9" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(Level
1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;March
31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;December
31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Financial
Assets:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Marketable
securities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Financial
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Deferred
compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,264&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,322&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="100%" colspan="9" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(Level
2)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Financial
Assets:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Short-term
cash investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,792&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,691&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Long-term
cash investments&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;870&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;820&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;Items
Measured at Fair Value on a Non-Recurring Basis:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#x2019;s
goodwill and other identifiable intangible assets are measured at
fair value on a nonrecurring basis using significant unobservable
inputs (Level 3) described in Note 3 &amp;#x2013; Goodwill and Other
Identifiable Intangible Assets. Goodwill and other identifiable
intangible assets with indefinite lives are reviewed for impairment
annually, and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. Long-lived assets
and identifiable intangible assets are also reviewed for impairment
whenever events or changes in circumstances indicate that amounts
may not be recoverable. If the testing performed indicates that
impairment has occurred, the Company records a non-cash impairment
charge for the difference between the carrying amount of the
goodwill or other intangible assets and the implied fair value of
the goodwill or other intangible assets in the period the
determination is made. Goodwill and other intangible assets
represented 86.6% and 86.9% of the Company&amp;#x2019;s
stockholders&amp;#x2019; equity as of March 31, 2012 and December 31,
2011, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">111000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">174000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-464000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">3508000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-1702000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">44000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">2125000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.02</us-gaap:EarningsPerShareBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-774000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:CostOfServices contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">93068000</us-gaap:CostOfServices>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">31120000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-190000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-463000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-2726000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-584000</us-gaap:NetIncomeLoss>
  <us-gaap:CostsAndExpenses contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">126710000</us-gaap:CostsAndExpenses>
  <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-190000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-23000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:AmortizationOfAcquisitionCosts contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">818000</us-gaap:AmortizationOfAcquisitionCosts>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.02</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-341000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">374000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">462000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-FAMILY: Times New Roman"&gt;3.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;GOODWILL
AND OTHER IDENTIFIABLE INTANGIBLE ASSETS&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company adopted
Update No. 2011-08, &lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Intangibles &amp;#x2014; Goodwill and Other (Topic 350), Testing
Goodwill for Impairment,&lt;/font&gt; (ASU 2011-08) for its condensed
consolidated financial statements in the first quarter of 2012. ASU
2011-08 allows the option to first assess qualitative factors to
determine whether it is more likely than not (a likelihood of more
than 50%) that the fair value of a reporting unit is less than its
carrying amount. If, after considering the totality of events and
circumstances, an entity determines it is not more likely than not
that the fair value of a reporting unit is less than its carrying
amount, performing the two-step impairment test is
unnecessary.&amp;#xA0;&amp;#xA0;The Company elected not to use this option
in its review of its goodwill and other intangible assets in the
first quarter of 2012 as the Company determined there were
indicators which triggered additional testing. See further
discussion which follows.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Interim Impairment Review of Goodwill and Indefinite-lived
Intangible Assets&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In accordance with
the &lt;font style="FONT-STYLE: italic"&gt;Intangibles-Goodwill and
Other&lt;/font&gt; Topic of the FASB ASC, the Company evaluates goodwill
and indefinite-lived intangible assets annually, in its fourth
quarter, for impairment at the reporting unit level and whenever
circumstances occur indicating that goodwill might be impaired. In
its impairment analysis, the Company determines the fair value of
its reporting units based on a combination of inputs including
Level 3 inputs such as discounted cash flows which are not
observable from the market, directly or indirectly, as well as
inputs such as pricing multiples from publicly traded guideline
companies and the market capitalization of the
Company.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;As of March 31,
2012, the Company determined there were indicators which triggered
an impairment analysis of its goodwill and indefinite-lived
intangible assets and, therefore, the Company completed the first
step of its goodwill impairment testing. At the end of the first
quarter of 2012, the Company&amp;#x2019;s stock price declined from
December 31, 2011. In addition, a slowdown in demand and booking
activity in the Company&amp;#x2019;s nurse and allied staffing segment
resulted in a downward revision to this segment&amp;#x2019;s near-term
forecast.&amp;#xA0;&amp;#xA0;Additionally, the Company was closely
monitoring performance in its clinical trial services and physician
staffing businesses due to a thin margin between the carrying
amount and fair value of those respective reporting units as of the
December 31, 2011 annual impairment testing.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The first step in
its impairment assessment requires the Company to determine the
fair value of each of its reporting units and compare it to the
reporting unit&amp;#x2019;s carrying amount.&amp;#xA0;&amp;#xA0;The Company
estimated the fair value of each of the reporting units based on a
weighting of both the income approach and the market approach
(blended fair value).&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The discounted cash
flows for each reporting unit that served as the primary basis for
the income approach were based on discrete financial forecasts
developed by management for planning purposes and consistent with
those distributed within the Company and externally. A number of
significant assumptions and estimates were involved in the
application of the income methodology including forecasted revenue,
margins, operating cash flows, discount rate, and working capital
changes. Cash flows beyond the discrete forecast period of ten
years were estimated using a terminal value calculation. A terminal
value growth rate of 2.5% was used for each reporting unit. The
income approach valuations included reporting unit cash flow
discount rates, representing each reporting unit&amp;#x2019;s weighted
average cost of capital, ranging from 11.0% to 18.7%.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The market approach
applied pricing multiples derived from publicly-traded guideline
companies that are comparable to the respective reporting unit, to
determine its value. The Company utilized total enterprise
value/revenue multiples ranging from 0.4 to 1.0 and total
enterprise value/Earnings Before Interest Taxes Depreciation and
Amortization (EBITDA) multiples ranging from 8.0 to 10.2. The
reporting units&amp;#x2019; market value were determined assuming a 50%
weighting to revenue multiples and a 50% weighting to EBITDA
multiples for its nurse and allied staffing, physician staffing and
clinical trial services reporting units; a 100% weighting to the
EBITDA multiples for the education and training reporting unit and
100% weighting to revenue multiples for its retained search
reporting unit.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Upon completion of
the first quarter 2012 assessment, the Company determined that the
estimated fair value of all of the Company&amp;#x2019;s reporting units
exceeded their respective carrying values as follows: nurse and
allied staffing &amp;#x2013; 2.4%, physician staffing &amp;#x2013; 8.7%,
clinical trial services &amp;#x2013; 6.2%, retained search &amp;#x2013; 38.5%
and education and training &amp;#x2013;132.2%. The Company&amp;#x2019;s
reporting units continue to generate positive cash flows from their
operations, and the Company expects that they will continue to do
so in fiscal 2012 and beyond.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The total fair
value of the reporting units was reconciled to the Company&apos;s March
31, 2012 market capitalization. The reasonableness of the resulting
control premium was assessed based on a review of comparative
market transactions and other qualitative factors that might have
influenced the Company&amp;#x2019;s share price. The Company&amp;#x2019;s
market capitalization was also considered in assessing the
reasonableness of the cumulative fair values of the reporting
units. In performing the reconciliation of the Company&amp;#x2019;s
market capitalization to fair value, the Company considered both
quantitative and qualitative factors which supported the implied
control premium. The Company believes that a reasonable potential
buyer would offer a control premium for the business that would
adequately cover the difference between its market price at March
31, 2012 and its book value. Based on the foregoing, the Company
concluded it did not have an impairment at March 31,
2012.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="shares" decimals="-3">30766000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;10.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;COMMITMENTS
AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;
Maureen Petray and Carina Higareda v. MedStaff, Inc.
(settled)&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;On
February&amp;#xA0;18, 2005, the Company&amp;#x2019;s MedStaff subsidiary
became the subject of a purported class action lawsuit
(&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Maureen
Petray and Carina Higareda v. MedStaff, Inc.)&lt;/font&gt; filed in the
Superior Court of California in Riverside County. The Court granted
final approval of the class settlement on March&amp;#xA0;18, 2011. The
Company had previously accrued a pre-tax charge of
$0.3&amp;#xA0;million (approximately $0.2&amp;#xA0;million after taxes)
related to this lawsuit. The final settlement amount was
$0.3&amp;#xA0;million, which was paid during the first quarter of
2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The lawsuit related
to only MedStaff corporate employees working in California. The
lawsuit alleged, among other things, violations of certain sections
of the California Labor Code, the California Business and
Professions Code, and recovery of unpaid wages and
penalties.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company is also
subject to other legal proceedings and claims that arise in the
ordinary course of its business. In the opinion of management, the
outcome of these other matters will not have a significant effect
on the Company&amp;#x2019;s consolidated financial position or results
of operations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;
Sales &amp;amp; Other State Non-income Tax Liabilities&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company&amp;#x2019;s
sales and other state non-income tax filings are subject to routine
audits by authorities in the jurisdictions where it conducts
business in the United States which may result in assessments of
additional taxes. During 2011, a state administrative ruling
related to certain service tax matters was released which indicated
that services performed in that particular state are subject to a
tax not previously paid by the Company. As a result, the Company
conducted an initial review of certain other states to determine if
any additional exposures may exist and determined that it was
probable that some of its previous tax positions would be
challenged. As a result, the Company changed its assessment of
certain non-income tax positions and estimated a liability related
to these matters. Based on its best estimate of probable
settlement, the Company accrued a pretax liability related to the
non-income tax matters of approximately $0.7 million in the year
ended December 31, 2011. During the three months ended March 31,
2012, based on revised estimates, the Company accrued an additional
pretax liability related to these non-income tax matters of
approximately $0.4 million, primarily related to the 2008-2011 tax
years. The expense is included in selling, general and
administrative expenses on its condensed consolidated statements of
operations and the liability is reflected in other current
liabilities on its condensed consolidated balance
sheets.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">-71000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:Depreciation contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">1593000</us-gaap:Depreciation>
  <us-gaap:PaymentsToAcquireOtherInvestments contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">89000</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;9.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;SEGMENT
DATA&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company reports
the following business segments in accordance with the &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Segment Reporting&lt;/font&gt; Topic of the FASB ASC:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 45pt"&gt;
&lt;div style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x25CF;&lt;/font&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Nurse and allied staffing -&lt;/font&gt; The nurse and allied staffing
business segment provides travel nurse and allied staffing services
and per diem nurse services primarily to acute care hospitals.
Nurse and allied staffing services are marketed to public and
private healthcare and for-profit and not-for-profit facilities
throughout the U.S.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 45pt"&gt;
&lt;div style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x25CF;&lt;/font&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Physician staffing &amp;#x2013;&lt;/font&gt; The&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;physician
staffing business segment provides multi-specialty locum tenens
services to the healthcare industry throughout the
U.S.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 45pt"&gt;
&lt;div style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x25CF;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Clinical trial services -&lt;/font&gt; The clinical trial services
business segment provides clinical trial, drug safety, and
regulatory professionals and services on a contract staffing and
outsourced basis to companies in the pharmaceutical, biotechnology
and medical device industries, as well as to contract research
organizations, primarily in the United States, and also in Canada
and Europe.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 45pt"&gt;
&lt;div style="TEXT-ALIGN: center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x25CF;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;
Other human capital management services -&lt;/font&gt; The other human
capital management services business segment includes the combined
results of the Company&amp;#x2019;s education and training and retained
search businesses that both have operations within the
U.S.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Information on
operating segments and a reconciliation to (loss)&amp;#xA0;income from
operations for the periods indicated are as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="26%" colspan="6"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Three
Months Ended&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="26%" colspan="6"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;March
31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="26%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(amounts
in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Revenue from
services:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Nurse and allied
staffing&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;69,537&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;66,857&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Physician
staffing&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;29,259&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;29,436&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Clinical trial
services&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;16,872&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;15,632&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Other human capital
management services&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;11,004&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;10,121&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="72%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;126,672&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;122,046&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Contribution income
(a):&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Nurse and allied
staffing (b)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;3,999&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;5,011&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Physician
staffing&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2,407&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2,762&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Clinical trial
services&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,323&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,292&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Other human capital
management services&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,110&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;390&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="72%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;8,839&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;9,455&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Unallocated
corporate overhead (b)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;6,466&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;5,588&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,593&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,841&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;818&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;965&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="72%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(Loss) income from
operations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(38&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1,061&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(a)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="74%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;The Company defines
contribution income as (loss) income from operations before
depreciation, amortization and corporate expenses not specifically
identified to a reporting segment. Contribution income is a
financial measure used by management when assessing segment
performance and is provided in accordance with the &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman"&gt;
Segment Reporting&lt;/font&gt; Topic of the FASB ASC.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(b)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="74%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;In 2011, the
Company refined its methodology for allocating certain corporate
overhead expenses to the nurse and allied staffing segment to more
accurately reflect this segment&amp;#x2019;s profitability. The segment
data for the three months ended March 31, 2011, has been
reclassified by $0.1 million to conform to the current year&amp;#x2019;s
presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;


&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">561000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
  <us-gaap:InterestExpense contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">629000</us-gaap:InterestExpense>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;1.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;ORGANIZATION
AND BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The accompanying
condensed consolidated financial statements include the accounts of
Cross Country Healthcare, Inc. and its direct and indirect
wholly-owned subsidiaries (collectively, the Company). All material
intercompany transactions and balances have been eliminated in
consolidation. The accompanying condensed consolidated financial
statements have been prepared in accordance with accounting
principles generally accepted in the United States for interim
financial information and with the instructions to Form&amp;#xA0;10-Q
and Article 10 of Regulation&amp;#xA0;S-X. Accordingly, they do not
include all of the information and notes required by U.S. generally
accepted accounting principles (U.S. GAAP) for complete financial
statements. The preparation of consolidated financial statements,
in conformity with U.S. GAAP, requires management to make estimates
and assumptions that affect the reported amounts in the condensed
consolidated financial statements and accompanying notes. Estimates
are used for, but not limited to, the valuation of accounts
receivable, goodwill and intangible assets, other long-lived
assets, accruals for health, workers&amp;#x2019; compensation and
professional liability claims, legal contingencies, income taxes
and sales and other non-income tax liabilities. Actual results
could differ from those estimates. In the opinion of management,
all adjustments (consisting of normal recurring accruals)
considered necessary for a fair presentation have been included.
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;These
operating results are not necessarily indicative of the results
that may be expected for the year ending December 31,
2012.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;These unaudited
interim condensed consolidated financial statements should be read
in conjunction with the audited consolidated financial statements
and notes thereto for the year ended December&amp;#xA0;31, 2011
included in the Company&amp;#x2019;s Annual Report on Form&amp;#xA0;10-K as
filed with the Securities and Exchange Commission. The
December&amp;#xA0;31, 2011 condensed consolidated balance sheet
included herein was derived from the December&amp;#xA0;31, 2011 audited
consolidated balance sheet included in the Company&amp;#x2019;s Annual
Report on Form&amp;#xA0;10-K.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Certain prior year
amounts have been reclassified to conform to the current period
presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3">561000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;6.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;DEBT&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;At March 31, 2012
and December&amp;#xA0;31, 2011, long-term debt consists of the
following:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;March
31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;December
31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="6%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="66%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="26%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;(amounts
in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td bgcolor="white" valign="bottom" width="6%" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Term loan, interest
2.00% at March 31, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;38,592&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;41,451&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td bgcolor="white" valign="bottom" width="6%" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;and
2.28% at December 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td bgcolor="white" valign="bottom" width="6%" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Revolving credit
facility, interest 5.50%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;600&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="6%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Capital lease
obligations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;545&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;595&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td bgcolor="white" valign="bottom" width="6%" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Total
debt&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;39,737&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;42,046&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="6%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Less current
portion&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(22,960&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(16,998&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" bgcolor="white" valign="bottom" width="6%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="66%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Long-term
debt&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;16,777&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;25,048&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;The Company has a
senior secured credit agreement which includes a term loan and a
revolving credit facility. In March 2012, the Company entered into
a third amendment to its Credit Agreement with the lenders party
thereto Wells Fargo Bank, National Association, as Administrative
Agent. The effect of the Credit Agreement amendment was to increase
the number of allowable share repurchases/dividends, using existing
cash and cash equivalents, when the Company&amp;#x2019;s Consolidated
Leverage Ratio (as defined), after giving effect to the
transaction, is less than 2.00 to 1.00 but equal to or greater than
1.00 to 1.00, and there are no outstanding revolving credit loans
(other than letters of credit obligations). Pursuant to the
amendment, the allowable amount has increased from an amount not to
exceed $2.5 million to an amount not to exceed $5.0 million in any
fiscal year.&amp;#xA0;The financing fees related to this amendment were
immaterial.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;As of March 31,
2012, the Company had $0.6 million outstanding under its $50.0
million revolving credit facility, and $12.6&amp;#xA0;million of
standby letters of credit outstanding under its facility, leaving
$36.8&amp;#xA0;million available for borrowing. As of March 31, 2012,
interest on its revolving credit facility was based on LIBOR plus a
margin of 3.25% or Base Rate (as defined by the Credit Agreement)
plus a margin of 2.25%. The Company is required to pay a quarterly
commitment fee on the average daily unused portion of the revolving
loan facility, which, as of March 31, 2012, was 0.50%. The interest
rate spreads on its term loan as of March 31, 2012 were based on
LIBOR plus a margin of 1.75% or Base Rate plus a margin of 0.75%.
The table below summarizes what the Company believes are the key
financial covenant requirements, as defined by the Credit
Agreement, as amended, and the Company&amp;#x2019;s corresponding actual
performance as of March 31, 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="50%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Requirements&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Actual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="50%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Maximum Permitted
Levarage Ratio (a)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2.50 to
1.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1.74 to
1.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Minimum Fixed
Charge Coverage Ratio (b)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1.25 to
1.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;1.83 to
1.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Maximum Capital
Expenditures for 2012 (c)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$8.0
million&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$3.6
million&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(a)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="74%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;The Company&amp;#x2019;s
Leverage Ratio must not be greater than 2.50 to 1.00 for the
duration of the Credit Agreement ending
September&amp;#xA0;2013.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(b)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="74%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;The Company&amp;#x2019;s
Fixed Charge Coverage Ratio (as defined by the Credit Agreement)
must not be less than: 1) 1.25 to 1.00 for the fiscal year 2012 and
2) 1.15 to 1.00 thereafter.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" width="4%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;(c)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="74%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;The Capital
Expenditures limit as defined by the Credit Agreement may be
increased in any fiscal year by the amount of Capital Expenditures
that were permitted but not made in the immediately preceding
fiscal year. The aggregate Capital Expenditures limit for the
fiscal years following as defined by the Credit Agreement are: 1)
$5.0&amp;#xA0;million in the fiscal year 2011 and 2) $7.0&amp;#xA0;million
in the fiscal year 2012. The 2012 limit in the preceding table
reflects an increase of $1.0 million representing the 2011 fiscal
year excess that was permitted but not made.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Long-term debt
includes capital lease obligations that are subordinate to the
Company&amp;#x2019;s senior secured facility.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Aggregate scheduled
maturities of long-term debt as of March 31, 2012, are as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="60%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="99%" colspan="4"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;Through
Year Ending December 31 (amounts in thousands)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="83%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;14,689&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;24,872&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;83&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;65&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2016&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="14%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;28&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="83%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="83%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;39,737&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;During the three
months ended March 31, 2012, the Company repaid a total of $2.9
million on its term loan.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-FAMILY: Times New Roman"&gt;5.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;ACQUISITIONS&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
MDA Holdings, Inc.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In
September&amp;#xA0;2008, the Company consummated the acquisition of
substantially all of the assets of privately-held MDA Holdings,
Inc. and its subsidiaries and all of the outstanding stock of
Jamestown Indemnity Ltd., a Cayman Island company and wholly-owned
subsidiary (collectively, MDA). As of March 31, 2012, an
indemnification escrow account of $3.6&amp;#xA0;million
exists.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="eol_PE88446---1210-Q0006_STD_91_20120331_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-FAMILY: Times New Roman"&gt;2.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;COMPREHENSIVE
INCOME&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;In June 2011, the
Financial Accounting Standard Board (FASB) issued Update No.
2011-05, &lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Comprehensive Income (Topic 220), Presentation of Comprehensive
Income&lt;/font&gt;, (ASU 2011-05). ASU 2011-05 eliminates the option to
report other comprehensive income and its components in the
statement of changes in stockholders&amp;#x2019; equity and requires an
entity to present the total of comprehensive income, the components
of net income and the components of other comprehensive income
either in a single continuous statement or in two separate but
consecutive statements. In December 2011, the FASB issued Update
No. 2011-12, &lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Comprehensive Income (Topic 220), Deferral of the Effective Date
for Amendments to the Presentation of Reclassifications of Items
Out of Accumulated&lt;/font&gt;&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Other Comprehensive Income in Accounting Standards Update No.
2011-05,&lt;/font&gt; (ASU 2011-12)&lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;,&lt;/font&gt;
which is effective for fiscal years, and interim periods within
those years, beginning after December 15, 2011.&amp;#xA0;&amp;#xA0;The
Company adopted ASU 2011-05 in the fourth quarter of 2011by
electing to present two separate but consecutive statements, and
adopted the portion of the update that requires the presentation of
reclassification items out of accumulated other comprehensive
income, pursuant to ASU 2011-12 in the first quarter of 2012. The
Company did not have any reclassification items out of accumulated
other comprehensive income in the three months ended March 31, 2012
or 2011.&amp;#xA0;&amp;#xA0;Accordingly, the adoption of ASU 2011-12 did
not impact the condensed consolidated financial statements in the
first quarter of 2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;Total comprehensive
income includes net (loss) income, foreign currency translation
adjustments and net changes in the fair value of marketable
securities available for sale, net of any related deferred taxes.
Certain of the Company&amp;#x2019;s foreign operations use their
respective local currency as their functional currency. In
accordance with the &lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Foreign Currency Matters&lt;/font&gt; Topic of the FASB Accounting
Standards Codification (ASC),&lt;font style="DISPLAY: inline; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;assets
and liabilities of these operations are translated at the exchange
rates in effect on the balance sheet date. Statement of operations
items are translated at the average exchange rates for the period.
The cumulative impact of currency translation is included in
accumulated other comprehensive loss in the accompanying condensed
consolidated balance sheets and was $2.8 million and
$3.4&amp;#xA0;million at March 31, 2012 and December&amp;#xA0;31, 2011,
respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <context id="eol_PE88446---1210-Q0006_STD_91_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_90_20110331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_0_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_0_20110331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="eol_PE88446---1210-Q0006_STD_0_20120430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
    </entity>
    <period>
      <instant>2012-04-30</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>